Table 1
The characteristic of the selected studies in the meta-analysis.
| AUTHOR | YEAR | REGION | AGE(YEARS) | SEX(M/F) | SAMPLE SIZE(N) | MICRORNA 21 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| CASE | CONTROL | CASE | CONTROL | CASE | CONTROL | CASE | CONTROL | |||
| Kontaraki JE | 2014 | Greece | 60.42 ± 9.6 | 56.69 ± 8.59 | 29/31 | 13/16 | 60 | 29 | 3.08 ± 0.32 | 2.06 ± 0.31 |
| Cengiz M | 2015 | Turkey | 47.3 ± 5.6 | 45.4 ± 5.3 | 15/13 | 18/10 | 28 | 28 | 84.40 ± 92.30 | 24.10 ± 5.30 |
| Kontaraki JE | 2015 | Greece | 62.51 ± 9.7 | 58.8 ± 8.3 | 50/52 | 14/16 | 102 | 30 | 2.75 ± 0.15 | 1.82 ± 0.20 |
| Jiabing L | 2016 | China | – | – | 90/0 | 90/0 | 90 | 90 | 7.87 ± 5.46 | 1.03 ± 0.80 |
| Ying W | 2017 | China | 55.28 ± 8.03 | 53.20 ± 5.71 | 26/24 | 25/25 | 50 | 50 | 33.00 ± 3.01 | 26.14 ± 1.03 |
| Wang X | 2017 | China | 48.2 ± 12.8 | 46.5 ± 10.3 | 38/29 | 10/40 | 55 | 20 | 1.29 ± 0.52 | 0.72 ± 0.39 |
| Hijmans JG | 2018 | America | 59 ± 2 | 56 ± 1 | 10/5 | 10/5 | 15 | 15 | 1.32 ± 0.25 | 2.50 ± 0.29 |
| Yildirim E | 2019 | Turkey | 46.5 ± 5.9 | 44.7 ± 5.7 | 19/13 | 20/12 | 32 | 32 | 81.90 ± 88.90 | 22.40 ± 23.80 |
| Kara SP | 2021 | Turkey | 52.67 ± 7.49 | 48.84 ± 9.35 | 9/21 | 9/23 | 30 | 32 | 3.20 ± 10.50 | 2.60 ± 5.50 |
| Suzuki K | 2022 | Japan | 62.3 ± 5.9 | 59.6 ± 9.7 | 13/16 | 20/35 | 29 | 55 | 0.89 ± 1.01 | 1.11 ± 1.73 |
| Shuang W | 2022 | China | 51.66 ± 7.84 | 50.84 ± 7.47 | 15/10 | 12/13 | 25 | 25 | 2.25 ± 0.87 | 1.44 ± 0.52 |
| Xin H | 2022 | China | 49.40 ± 10.27 | 41.86 ± 10.10 | 39/61 | 52/48 | 30 | 30 | 1.42 ± 1.18 | 0.88 ± 0.66 |
Figure 1
Flowchart of the detailed procedure for the inclusion or exclusion of selected studies.
Figure 2
Forest plots of micro-RNA 21 levels in patients with hypertension compared with the controls. Diamond represents standardized mean differences (SMDs) at 95% confidence intervals (CIs).
Figure 3
The sensitivity analysis results of micro-RNA 21 levels in patients with hypertension compared with the controls.